ArticleJournal of molecular histology2026
Stigmasterol glucoside attenuates RANKL-induced osteoclastogenesis and bone resorption by suppressing MAPK and STAT3 signaling pathways: an integrative pharmacological study.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a metabolic bone disease characterized by excessive osteoclast-mediated bone resorption. Stigmasterol glucoside (SG), a glycosylated phytosterol with enhanced hydrophilicity, has shown potential anti-inflammatory activities, but its role in bone metabolism remains largely unexplored. This study aimed to investigate the effects and underlying mechanisms of SG on osteoclastogenesis. An integrative pharmacological strategy was employed, combining network pharmacology and molecular docking to predict potential targets. These predictions were validated using primary bone marrow-derived macrophages (BMMs). Osteoclast differentiation and function were assessed via TRAcP staining, F-actin ring immunofluorescence, and bone resorption pit assays. Molecular mechanisms were elucidated using RT-qPCR, Western blotting, and luciferase reporter assays. Network pharmacology and molecular docking identified MAPK and STAT3 signaling axes as the core targets of SG, with high binding affinities for MAP2K1, JAK2, and STAT3. In vitro experiments demonstrated that SG dose-dependently inhibited RANKL-induced osteoclast differentiation and bone resorptive activity without cytotoxicity. At the molecular level, SG suppressed the expression and transcriptional activity of the master regulators NFATc1 and c-Fos, leading to the downregulation of essential functional markers. Further mechanistic investigations revealed that these inhibitory effects were driven by the attenuation of early-stage phosphorylation in the MAPK (p38, JNK, and ERK) and STAT3 signaling axes. SG effectively suppresses osteoclastogenesis and resorptive function by simultaneously intercepting the MAPK and STAT3/NFATc1 signaling axes. These findings provide experimental evidence that SG is a promising natural pharmacological candidate for the treatment of osteoporosis and bone loss-related disorders.
Indexed as
Identifiers
42371230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.